This workshop, sponsored by Thermo Fisher Scientific, is part of the Association of Molecular Pathology's AMP 2020 virtual conference held November 16-20, 2020.
Speaker: Kelli S. Bramlett, Director, R&D Life Sciences Solution Group, Thermo Fisher Scientific
Duration: 39 minutes
Overview:
Liquid Biopsy is a non-invasive method for identifying biomarkers present in circulating tumor DNA (ctDNA). Recent ctDNA detectiontechnologies could potentially revolutionize early cancer detection. As liquid biopsy technologies become more sensitive, screening for early cancer detection using a blood test could become routine clinical practice. However, with the advent of new technologies comes an equally important need for novel reference materials and quality assessment schemes to ensure quality test implementation.
Complete the form below to access the webinar recording.
CE credit not available for this webinar.
